Patient Support is
Available at Every
Step of Your
Journey Patient Support is Available at
Every Step of Your Journey
Available at Every
Step of Your
Journey
Every Step of Your Journey
How do I get YIMMUGO®?
YIMMUGO is available through a network of specialty pharmacies
Coverage assistance for YIMMUGO
Contact us for assistance with YIMMUGO, coverage programs, or reimbursement support:
Kedrion information line:
Commonly asked questions
Here are a few commonly asked questions about YIMMUGO. Talk to your doctor about any additional questions you may have based on your treatment needs.
How active can I be while taking YIMMUGO?
Is there anything I should bring to my infusion?
You should bring water to make sure you stay hydrated before your infusion1 and dress comfortably.
Since your infusion time may vary, it’s important that you have what you need to be comfortable. You can bring something to help you pass the time, whether it’s a tablet to watch a show on, headphones to listen to music or a podcast, a book, a laptop to catch up on work, or a cozy pillow and blanket to help you relax.
What are the most common side effects of YIMMUGO?
The most common side effect of YIMMUGO in the clinical trial was headache. Other common side effects include upper respiratory tract infections, nausea, fatigue, and increased blood pressure.1
Does YIMMUGO impact fertility?
YIMMUGO Welcome Brochure
How can I connect with others?
The following list of patient advocacy groups can help support you on your journey with PI.
-
The Immune Deficiency Foundation (IDF) improves the diagnosis, treatment, and quality of life for every person affected by PI. The IDF fosters a community that is connected, engaged, and empowered through advocacy, education, and research. -
The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international nonprofit organization and the leading worldwide advocate for people with PI. -
The Jeffrey Modell Foundation is a global nonprofit dedicated to early diagnosis, meaningful treatments and, ultimately, cures through basic and clinical research, physician and patient education, public awareness, government advocacy, patient support, newborn screening, and genetic sequencing. -
The Immunoglobulin National Society (IgNS) is a professional organization dedicated to the advancement of Ig therapy practice across clinical indications and areas of practice.
What is YIMMUGO®?
YIMMUGO (immune globulin intravenous, human – dira) is an immune globulin (Ig) liquid used to treat primary humoral immunodeficiency in people 2 years of age and older.
IMPORTANT SAFETY INFORMATION
YIMMUGO may cause:
- Blood clots (thrombosis). Blood clots may occur in people taking Ig intravenous (IGIV) products, including YIMMUGO. You may be at greater risk for blood clots if you are older, sit or lie for long periods, have a clotting condition or a history of blood clots, take estrogen, have a central catheter, have thick blood, and/or if you have other conditions that put you at risk for cardiovascular disease. Blood clots may occur even if you do not have any of these risk factors. Your healthcare provider should monitor you for signs and symptoms of blood clotting.
- Impaired kidney function or kidney failure. IGIV products, particularly those that contain sugar (sucrose), have been associated with kidney dysfunction and damage, kidney failure, and death. Kidney damage and failure are more common in people receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. You may be at greater risk for kidney failure if you have kidney disease, diabetes, are seriously dehydrated, overweight, take drugs that may damage your kidneys, or are over age 65. Your healthcare provider should monitor your kidney function before and periodically after your first infusion.
Do NOT use YIMMUGO if:
- You have a history of severe hypersensitivity or a history of allergic reactions to human Ig. Tell your healthcare provider if you have had a serious reaction to other medicines that contain human Ig or ask if you are not sure.
- You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, or have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.
WARNINGS AND PRECAUTIONS
- Severe allergic reactions may occur. People with IgA deficiency who have antibodies against IgA may be at greater risk of these reactions.
- Blood damage called hemolysis and hemolytic anemia can develop after treatment with YIMMUGO. Your healthcare provider should monitor you for signs and symptoms.
- If you are at risk of developing kidney damage or failure, your healthcare provider should monitor your kidney function before and periodically after your first infusion.
- You could experience higher-than-normal levels of protein in your blood, thick blood, or low sodium (salt) in your blood. This may prevent your blood from flowing easily and possibly lead to blood clots.
- Brain swelling called aseptic meningitis syndrome may occur infrequently with IGIV products, especially if you receive a high dose or a rapid infusion.
- Swelling of the lungs may occur following treatment. Your healthcare provider should monitor you for signs of lung damage.
- YIMMUGO is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
- Be sure to tell your healthcare provider about your recent history of vaccinations. Live vaccines for diseases like measles, mumps, rubella, and varicella may not work as well while receiving YIMMUGO. Tell your healthcare provider that you are taking YIMMUGO before you receive any vaccination.
ADVERSE REACTIONS
The most common side effects of YIMMUGO were headache, upper respiratory tract infections, fatigue, nausea, and increased blood pressure. During treatment with YIMMUGO, be sure to tell your healthcare provider about any unusual symptoms you experience, as they may indicate a possible side effect.
To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information for complete prescribing details, including Boxed Warning.